Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | GUSB | P08236 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21294915 | 0.83 | SCN9A (0.38) | HTR2CGUSBDRD2HCRTR2 | |
| SCHEMBL21294889 | 0.83 | KDM1A (0.39) | HTR2CGUSBHCRTR2KMT2APOLB | |
| SCHEMBL23140857 | 0.77 | HTR2C (0.49) | HTR2CDRD2HCRTR2CCR2 | |
| SCHEMBL28319367 | 0.75 | HTR2C (0.40) | HTR2CGUSBDRD2HCRTR2MAOA | |
| SCHEMBL28487048 | 0.75 | SCN9A (0.46) | HTR2CGUSBDRD2HCRTR2TACR1 | |
| SCHEMBL20063922 | 0.73 | HTR2C (0.52) | HTR2CDRD2MAOAMAOB | |
| SCHEMBL21294827 | 0.73 | HTR2C (0.44) | HTR2CDRD2POLBCCR2 | |
| SCHEMBL20063931 | 0.72 | HTR2C (0.49) | HTR2CDRD2 | |
| SCHEMBL21296536 | 0.72 | HTR2C (0.49) | HTR2CDRD2 | |
| Hydrochloric Acid SCHEMBL23140795 | 0.72 | HTR2C (0.54) | HTR2CDRD2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | ASAH2, ACER2, PCSK9 | HTR2C 2475/4885GUSB 268/4885DRD2 3912/4885 |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | TRPV1, HCN4, TRPA1 | HTR2C 823/4885GUSB 695/4885DRD2 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.